{"disease":{"id":"polycythemia-vera-and-essential-thrombocythemia-thromboembolism-prevention","name":"polycythemia vera and essential thrombocythemia thromboembolism prevention"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Polycythemia vera and essential thrombocythemia (thromboembolism prevention)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}